Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
F, P, IF, WB |
Verdünnung |
1:20 - 1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Whole cell preparation from B. burgdorferi |
Borrelia burgdorferi
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
602-0115 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
IF, WB |
Isotyp |
Rabbit IgG |
Verdünnung |
Native, whole cells |
Borrelia burgdorferi - FITC
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
602-0118C |
-
|
Host |
Mouse |
Klon |
VE1 |
Format |
Concentrate |
Reaktivität |
CK, FG, MS |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma with BRAF V600E mutation |
Verdünnung |
1:100 |
Verdünnung |
Synthetic peptide representing the BRAF V600E mutated amino acid sequence from amino acid 596 to 606 (GLATEKSRWSG). |
BRAF V600E
|
Abcam |
VE1 |
0.1 ml |
Concentrate |
RUO |
AB228461-0.1 ML |
-
|
Host |
Mouse |
Klon |
VE1 |
Format |
Concentrate |
Reaktivität |
CK, FG, MS |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma with BRAF V600E mutation |
Verdünnung |
1:100 |
Verdünnung |
Synthetic peptide representing the BRAF V600E mutated amino acid sequence from amino acid 596 to 606 (GLATEKSRWSG). |
BRAF V600E
|
Abcam |
VE1 |
0.5 ml |
Concentrate |
RUO |
AB228461-0.5 ML |
-
|
Host |
Mouse |
Klon |
VE1 |
Format |
Concentrate |
Reaktivität |
CK, FG, MS |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma with BRAF V600E mutation |
Verdünnung |
1:100 |
Verdünnung |
Synthetic peptide representing the BRAF V600E mutated amino acid sequence from amino acid 596 to 606 (GLATEKSRWSG). |
BRAF V600E
|
Abcam |
VE1 |
1 ml |
Concentrate |
RUO |
AB228461-1.0 ML |
-
|
Host |
Mouse |
Klon |
MS110 |
Format |
Purified |
Methode |
F, P, FL, WB, IF, IP |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast carcinoma |
Isotyp |
Mouse IgG1 |
Verdünnung |
Recombinant protein corresponding to the N-Terminal region of human BRCA1 |
BRCA1
|
Zytomed Systems GmbH |
MS110 |
50 µg (1 mg/ml) |
Purified |
RUO |
602-0170 |
-
|
Host |
Mouse |
Klon |
GLK-2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Ovary Carcinoma |
Verdünnung |
1:15 - 1:50 |
Isotyp |
Mouse IgM |
Lokalisation |
Cytoplasm |
BRCA1
|
Diagnostic Biosystems |
GLK-2 |
1 ml |
Concentrate |
RUO |
MOB424 |
-
|
Host |
Mouse |
Klon |
GLK-2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Ovary Carcinoma |
Verdünnung |
1:15 - 1:50 |
Isotyp |
Mouse IgM |
Lokalisation |
Cytoplasm |
BRCA1
|
Diagnostic Biosystems |
GLK-2 |
0.1 ml |
Concentrate |
RUO |
MOB424-01 |
-
|
Host |
Mouse |
Klon |
GLK-2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Ovary Carcinoma |
Verdünnung |
1:15 - 1:50 |
Isotyp |
Mouse IgM |
Lokalisation |
Cytoplasm |
BRCA1
|
Diagnostic Biosystems |
GLK-2 |
0.5 ml |
Concentrate |
RUO |
MOB424-05 |
-
|
Host |
Mouse |
Klon |
MS110 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma with BRCA-1 gene mutation. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
BRCA-1 |
Lokalisation |
Nucleus |
BRCA1
|
Zeta Corporation |
MS110 |
1 ml |
Concentrate |
CE/IVD |
Z2237ML |
-
|
Host |
Mouse |
Klon |
MS110 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma with BRCA-1 gene mutation. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
BRCA-1 |
Lokalisation |
Nucleus |
BRCA1
|
Zeta Corporation |
MS110 |
7 ml |
Ready-to-use |
CE/IVD |
Z2237MP |
-
|
Host |
Mouse |
Klon |
MS110 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma with BRCA-1 gene mutation. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
BRCA-1 |
Lokalisation |
Nucleus |
BRCA1
|
Zeta Corporation |
MS110 |
0.5 ml |
Concentrate |
CE/IVD |
Z2237MS |
-
|
Host |
Mouse |
Klon |
MS110 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma with BRCA-1 gene mutation. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
BRCA-1 |
Lokalisation |
Nucleus |
BRCA1
|
Zeta Corporation |
MS110 |
0.1 ml |
Concentrate |
CE/IVD |
Z2237MT |
-
|
Host |
Mouse |
Klon |
Bu20a |
Format |
Purified |
Methode |
F, P, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Bromodeoxyuridine conjugated to BSA |
Bromodeoxyuridine (BrdU)
|
Zytomed Systems GmbH |
Bu20a |
200 µg |
Purified |
RUO |
602-0135 |
-
|
Host |
Mouse |
Klon |
Bu20a |
Format |
Purified |
Methode |
F, P, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Bromodeoxyuridine conjugated to BSA |
Bromodeoxyuridine (BrdU)
|
Zytomed Systems GmbH |
Bu20a |
20 µg |
Purified |
RUO |
602-0180 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P,F |
Verdünnung |
1:20 - 1:40 |
Isotyp |
Rabbit Ig |
C1q-FITC
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
F010 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P,F |
Verdünnung |
1:20 - 1:40 |
Isotyp |
Rabbit Ig |
C1q-FITC
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
F010-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P,F |
Verdünnung |
1:75 - 1:100 |
Isotyp |
Rabbit Ig |
C3c-FITC
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
F003 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P,F |
Verdünnung |
1:75 - 1:100 |
Isotyp |
Rabbit Ig |
C3c-FITC
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
F003-01 |
-
|
Host |
Mouse |
Klon |
ZM369 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Acute rejected kidney transplant |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b/κ |
Verdünnung |
Recombinant full-length human Complement C3 protein |
Lokalisation |
Membrane or Cytoplasm |
C3d
|
Zeta Corporation |
ZM369 |
1 ml |
Concentrate |
CE/IVD |
Z2660ML |
-
|
Host |
Mouse |
Klon |
ZM369 |
Format |
ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Acute rejected kidney transplant |
Verdünnung |
--- |
Isotyp |
IgG2b/κ |
Verdünnung |
Recombinant full-length human Complement C3 protein |
Lokalisation |
Membrane or Cytoplasm |
C3d
|
Zeta Corporation |
ZM369 |
7 ml |
ready-to-use |
CE/IVD |
Z2660MP |
-
|
Host |
Mouse |
Klon |
ZM369 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Acute rejected kidney transplant |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b/κ |
Verdünnung |
Recombinant full-length human Complement C3 protein |
Lokalisation |
Membrane or Cytoplasm |
C3d
|
Zeta Corporation |
ZM369 |
0.5 ml |
Concentrate |
CE/IVD |
Z2660MS |
-
|
Host |
Mouse |
Klon |
ZM369 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Acute rejected kidney transplant |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b/κ |
Verdünnung |
Recombinant full-length human Complement C3 protein |
Lokalisation |
Membrane or Cytoplasm |
C3d
|
Zeta Corporation |
ZM369 |
0.1 ml |
Concentrate |
CE/IVD |
Z2660MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P,F |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit Ig |
C4c-FITC
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
F005 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P,F |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit Ig |
C4c-FITC
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
F005-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Verdünnung |
1:50 |
Isotyp |
Rabbit Ig |
Verdünnung |
Synthetic peptide specific for human complement C4d conjugated to KLH (keyhole limpet hemocyanin) |
C4d
|
Zytomed Systems GmbH |
polyclonal |
250 µl |
Concentrate |
RUO |
A12-5000 |
-
|
Host |
Mouse |
Klon |
ZM78 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Acute rejected kidney transplant. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant full-length human complement 4d protein |
Lokalisation |
Membrane or Cytoplasm |
C4d (Complement factor)
|
Zeta Corporation |
ZM78 |
1 ml |
Concentrate |
CE/IVD |
Z2388ML |
-
|
Host |
Mouse |
Klon |
ZM78 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Acute rejected kidney transplant. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant full-length human complement 4d protein |
Lokalisation |
Membrane or Cytoplasm |
C4d (Complement factor)
|
Zeta Corporation |
ZM78 |
7 ml |
Ready-to-use |
CE/IVD |
Z2388MP |
-
|
Host |
Mouse |
Klon |
ZM78 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Acute rejected kidney transplant. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant full-length human complement 4d protein |
Lokalisation |
Membrane or Cytoplasm |
C4d (Complement factor)
|
Zeta Corporation |
ZM78 |
0.5 ml |
Concentrate |
CE/IVD |
Z2388MS |
-
|
Host |
Mouse |
Klon |
ZM78 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Acute rejected kidney transplant. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant full-length human complement 4d protein |
Lokalisation |
Membrane or Cytoplasm |
C4d (Complement factor)
|
Zeta Corporation |
ZM78 |
0.1 ml |
Concentrate |
CE/IVD |
Z2388MT |
-
|
Host |
Mouse |
Klon |
C4D204 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
rejected kidney |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Verdünnung |
A recombinant fragment specific to Complement 4d |
Lokalisation |
Cell membrane, Cytoplasm |
C4d Komplementfaktor
|
Diagnostic Biosystems |
C4D204 |
1 ml |
Concentrate |
CE/IVD |
MOB471 |
-
|
Host |
Mouse |
Klon |
C4D204 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
rejected kidney |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Verdünnung |
A recombinant fragment specific to Complement 4d |
Lokalisation |
Cell membrane, Cytoplasm |
C4d Komplementfaktor
|
Diagnostic Biosystems |
C4D204 |
0.1 ml |
Concentrate |
CE/IVD |
MOB471-01 |
-
|
Host |
Mouse |
Klon |
C4D204 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
rejected kidney |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Verdünnung |
A recombinant fragment specific to Complement 4d |
Lokalisation |
Cell membrane, Cytoplasm |
C4d Komplementfaktor
|
Diagnostic Biosystems |
C4D204 |
0.5 ml |
Concentrate |
CE/IVD |
MOB471-05 |
-
|
Host |
Mouse |
Klon |
DBMM1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Breast carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm, cell membrane |
CA 15-3
|
Diagnostic Biosystems |
DBMM1 |
1 ml |
Concentrate |
CE/IVD |
MOB549 |
-
|
Host |
Mouse |
Klon |
DBMM1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Breast carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm, cell membrane |
CA 15-3
|
Diagnostic Biosystems |
DBMM1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB549-01 |
-
|
Host |
Mouse |
Klon |
DBMM1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Breast carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm, cell membrane |
CA 15-3
|
Diagnostic Biosystems |
DBMM1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB549-05 |
-
|
Host |
Mouse |
Klon |
DBMM1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Breast carcinoma |
Verdünnung |
- |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm, cell membrane |
CA 15-3
|
Diagnostic Biosystems |
DBMM1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM549 |
-
|
Host |
Mouse |
Klon |
C241:5:1:4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
CA 19-9 Antigen (Colon)
|
Diagnostic Biosystems |
C241:5:1:4 |
1 ml |
Concentrate |
CE/IVD |
MOB109 |
-
|
Host |
Mouse |
Klon |
C241:5:1:4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
CA 19-9 Antigen (Colon)
|
Diagnostic Biosystems |
C241:5:1:4 |
0.1 ml |
Concentrate |
CE/IVD |
MOB109-01 |
-
|
Host |
Mouse |
Klon |
C241:5:1:4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
CA 19-9 Antigen (Colon)
|
Diagnostic Biosystems |
C241:5:1:4 |
0.5 ml |
Concentrate |
CE/IVD |
MOB109-05 |
-
|
Host |
Mouse |
Klon |
B72.3 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, Cell Surface |
CA 72.4 Antigen (TAG-72, BRST3)
|
Diagnostic Biosystems |
B72.3 |
1 ml |
Concentrate |
CE/IVD |
MOB288 |
-
|
Host |
Mouse |
Klon |
B72.3 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, Cell Surface |
CA 72.4 Antigen (TAG-72, BRST3)
|
Diagnostic Biosystems |
B72.3 |
0.1 ml |
Concentrate |
CE/IVD |
MOB288-01 |
-
|
Host |
Mouse |
Klon |
B72.3 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, Cell Surface |
CA 72.4 Antigen (TAG-72, BRST3)
|
Diagnostic Biosystems |
B72.3 |
0.5 ml |
Concentrate |
CE/IVD |
MOB288-05 |
-
|
Host |
Mouse |
Klon |
B72.3 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, Cell Surface |
CA 72.4 Antigen (TAG-72, BRST3)
|
Diagnostic Biosystems |
B72.3 |
6 ml |
Ready-to-use |
CE/IVD |
PDM100 |
-
|
Host |
Mouse |
Klon |
Ov185:1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Ovary Carcinoma, AdenoCarcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Extracellular Membrane |
CA 125 Antigen (Ovary)
|
Diagnostic Biosystems |
Ov185:1 |
1 ml |
Concentrate |
CE/IVD |
MOB110 |
-
|
Host |
Mouse |
Klon |
Ov185:1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Ovary Carcinoma, AdenoCarcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Extracellular Membrane |
CA 125 Antigen (Ovary)
|
Diagnostic Biosystems |
Ov185:1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB110-01 |
-
|
Host |
Mouse |
Klon |
Ov185:1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Ovary Carcinoma, AdenoCarcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Extracellular Membrane |
CA 125 Antigen (Ovary)
|
Diagnostic Biosystems |
Ov185:1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB110-05 |
-
|
Host |
Mouse |
Klon |
ZM53 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Ovarian carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Full length native CA125 protein purified from human ovarian carcinoma |
Lokalisation |
Extracellular membrane-associated. |
CA 125/ MUC16
|
Zeta Corporation |
ZM53 |
1 ml |
Concentrate |
CE/IVD |
Z2363ML |
-
|
Host |
Mouse |
Klon |
ZM53 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Ovarian carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Full length native CA125 protein purified from human ovarian carcinoma |
Lokalisation |
Extracellular membrane-associated. |
CA 125/ MUC16
|
Zeta Corporation |
ZM53 |
7 ml |
Ready-to-use |
CE/IVD |
Z2363MP |
-
|
Host |
Mouse |
Klon |
ZM53 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Ovarian carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Full length native CA125 protein purified from human ovarian carcinoma |
Lokalisation |
Extracellular membrane-associated. |
CA 125/ MUC16
|
Zeta Corporation |
ZM53 |
0.5 ml |
Concentrate |
CE/IVD |
Z2363MS |
-
|